Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 104951_HPV

Result Summary for 104951_HPV

Result Summary

Protocol ID:	104951_HPV
Clinical Study ID:	104951
Official Title:	Evaluate the immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0,1,6 mth schedule in healthy female subjects aged 10–14 yrs
Phase:	phase 3
Study Indications or Diseases:	Human Papillomavirus (HPV)
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Kim YJ et al. (2010) Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10–14 years. J Korean Med Sci. 25:1197-1204. Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638.